key: cord-0796926-acyexmyq
authors: Rocco, Patricia R. M.; Silva, Pedro L.; Cruz, Fernanda F.; Junior, Marco Antonio C. M.; Tierno, Paulo F. G. M. M.; Moura, Marcos A.; De Oliveira, Luís Frederico G.; Lima, Cristiano C.; Dos Santos, Ezequiel A.; Junior, Walter F.; Fernandes, Ana Paula S. M.; Franchini, Kleber G.; Magri, Erick; de Moraes, Nara F.; Gonçalves, José Mário J.; Carbonieri, Melanie N.; Dos Santos, Ivonise S.; Paes, Natália F.; Maciel, Paula V. M.; Rocha, Raissa P.; de Carvalho, Alex F.; Alves, Pedro Augusto; Modena, José Luiz P.; Cordeiro, Artur T.; Trivella, Daniela B. B.; Marques, Rafael E.; Luiz, Ronir R.; Pelosi, Paolo; Lapa e Silva, Jose Roberto
title: Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial
date: 2020-12-24
journal: Eur Respir J
DOI: 10.1183/13993003.03725-2020
sha: ec8d1df3732cda539e932c4b69eb721ca0ad52db
doc_id: 796926
cord_uid: acyexmyq

Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection. In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After confirmation of SARS-CoV2 infection by RT-PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation, and hospitalisation rate. Adverse events were also assessed. From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median time from symptom onset to first dose of study drug was 5 (4–5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). The percent viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed. In patients with mild Covid-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.

The majority of patients infected with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) present mild symptoms of coronavirus disease 2019 and recover with supportive care; however, in certain hosts, even mild disease may progress to clinical deterioration or a protracted course [1] . To date, no therapeutic interventions have proven effective in mild Covid-19.

Drug repurposing has been recognized as an important tool in the search for effective Covid-19 therapies, as it reduces development costs and timelines [2] . Nitazoxanide, a clinically approved and commercially available antiparasitic drug, has been found to have broad-spectrum antiviral activity, including against coronaviruses, influenza viruses, and hepatitis B and C viruses [3] . Furthermore, it has been shown to inhibit SARS-CoV-2 replication at low micromolar concentrations in Vero CCL81 cells [4] . In addition, nitazoxanide is orally bioavailable and broadly well-tolerated, thus representing a promising alternative for the management of Covid-19 were it to prove effective in vivo [3] . Efficacy in early treatment-initiated soon after symptom onset to reduce viral load and prevent disease progression-would be particularly appealing from a public health standpoint. However, there is no evidence of its safety or efficacy as therapy for mild Covid-19 patients.

In this context, a multicenter, randomized, placebo-controlled trial was carried out to evaluate whether early nitazoxanide therapy would be effective in accelerating symptom resolution. Secondarily, viral load, markers of inflammation, hospitalization rate, and the safety of nitazoxanide as compared with placebo were also assessed.

A double-blind, placebo-controlled trial was conducted at 5 freestanding urgent care centers and 2 hospitals across Brazil (supplementary table S1). 

Consecutive adult patients (aged 18 years or older) who presented with clinical symptoms of Covid-19 (defined for the purposes of this trial as dry cough, fever, and/or fatigue) of no longer than 3 days' duration were enrolled. The exclusion criteria were:

negative reverse-transcriptase quantitative real-time polymerase chain reaction (RT-PCR) test for SARS-CoV-2 on an nasopharyngeal swab specimen; inability to swallow; preexisting conditions precluding the safe conduct of study procedures, including severe renal, heart, respiratory, liver, or autoimmune diseases, cancer in the last 5 years, or known allergy or hypersensitivity to nitazoxanide; therapy with nitazoxanide in the 30 days before presentation; and clinical suspicion of bacterial pneumonia or tuberculosis.

Patients were randomly assigned (1:1) using a computer-generated random number list to receive either placebo or nitazoxanide (500 mg oral solution, 20 mg/mL [25 mL], three times daily for 5 days), dispensed by the pharmacy of each study site. Placebo and nitazoxanide were color-matched to ensure that assessors were unaware of group allocation at all time points.

On day 0 (baseline), patients were assessed for eligibility. Informed consent was obtained from each patient or, if the patient was unable to provide consent, from a healthcare proxy. A nasopharyngeal swab was then collected for RT-PCR testing. In order to mitigate any bias, all RT-PCR analyses were processed centrally at CT-VACINAS, Federal University of Minas Gerais, Brazil; specimens were sent on the day of collection by commercial courier. Patients who tested positive for SARS-CoV-2 (result obtained 1-2 days after RT-PCR) (figure 1) were contacted by telephone and asked to return to the health facility to which they had originally presented. Site investigators then performed a comprehensive physical examination and measured body temperature, heart and respiratory rates, blood pressure, and peripheral oxygen saturation. Ethnicity, current medications, and date of symptom onset were self-reported by patients. Blood was then drawn for measurement of complete blood count, C- All patients took home a symptom journal designed to gather information on daily symptoms, new symptoms, and the date of resolution of each symptom (supplementary table S2). Study data were entered directly into an electronic database by an assigned staff member at each study site and further validated by external trial monitoring staff at ATCGen.

One day after completion of therapy, patients returned to the study sites to return their symptom journals and provide a new nasopharyngeal sample for RT-PCR and blood samples for complete blood count, CRP, and serum biomarkers. Data validation was done exclusively by the designated study site manager, with assistance from ATCGen staff as needed.

The primary outcome was complete resolution of the three symptoms of interest (dry cough, fever, and/or fatigue) after 5 days of therapy.

Secondary outcomes were reduction in viral RNA load on nasopharyngeal swab specimens (from baseline until the day after completion of therapy); improvement in laboratory parameters (including serum biomarkers of inflammation); and incidence of hospital admission after completion of therapy. Patients who did not return to the study sites either to receive the therapy or after the end of therapy were contacted by telephone to understand the reasons for nonadherence and were then excluded from perprotocol analysis (Supplemental Methods). Adverse events, regardless of grade, were monitored throughout the trial by review of the electronic medical record, physical examination, vital signs, and laboratory tests from enrollment through day 14. The Medical Dictionary for Regulatory Activities® (MedDRA, version 23.0) was used for classification.

We estimated a sample size of 392 patients (196 per arm, allocation ratio 1:1) would provide 85% power to detect an 11% increase in symptom-free days after nitazoxanide initiation compared to placebo at a two-sided significance level of α=0.05. Descriptive statistics were used for demographic, laboratory, and clinical data. For qualitative variables, Fisher's exact test was performed. The Mann-Whitney U and Wilcoxon tests were used for between and within-groups comparisons, respectively. Statistical analyses were performed in the SPSS Version 27 environment (IBM Corp, Armonk, NY), and a two-tailed p-value < 0.05 was considered significant (Supplemental Methods).

Between June 8 and August 20, 2020, 1,575 patients were assessed for eligibility at the study sites. Of these, 475 tested positive for SARS-CoV-2 infection by RT-PCR and underwent randomization. Figure 2 summarizes the enrollment and follow-up of study participants. Reasons for exclusion before randomization included negative RT -PCR collected at day 0 and/or absence of Covid-19 symptoms (n=1,062), refusal to participate (n=27), hospitalization before the first dose of therapy (n=5), and other reasons (n=6). After randomization (n=475), patients were excluded due to discontinued intervention (n=41), moderate adverse events (n=7), and hospitalization (n=10). Six patients in the nitazoxanide arm and one patient in the placebo arm discontinued therapy due to moderate diarrhea and vomiting within the first 2 days; both had already experienced improvement of Covid-19 symptoms. Ten patients (5 from each arm) were hospitalized due to clinical deterioration; none had completed the 5-day course of therapy. Two patients, both in the nitazoxanide arm, required intensive care unit admission (supplementary table S3). During analysis, 12 patients were excluded from the nitazoxanide arm and 15 from the placebo arm due to protocol deviation, missing data on the primary outcome, or non-evaluability, resulting in a studied population of 392 patients (194 in the nitazoxanide arm and 198 in the placebo arm).

Patients' characteristics at baseline are given in table 1. Demographics and clinical characteristics were balanced in both groups. Age ranged from 18 to 77 years. Just over half (53%) were women and 69% were white. Regarding timing of therapy initiation, 8% of patients were enrolled on day 1, 25% on day 2, and 67% on day 3 after symptom onset. The median (IQR) time between symptom onset and first dose of nitazoxanide or placebo was 5 (4-5) days. Fever, dry cough, and fatigue were the most frequent clinical features present at enrollment. At baseline, the overall median (IQR) viral load in the nasopharyngeal swab at baseline did not differ significantly between the two arms Additional characteristics of the study population at baseline are given in supplementary table S4.

Complete resolution of symptoms (dry cough, fever, and fatigue) did not differ between the nitazoxanide and placebo arms after 5 days of therapy (figure 3, supplementary figure S2).

After 5 days of therapy, viral load was lower in the nitazoxanide arm compared to placebo (p=0.006) ( No deaths or life-threatening adverse events were reported in either arm. Mild and moderate adverse events were experienced by patients in both arms (nitazoxanide, 30.9%; placebo, 30.4%) during the 5-day course of therapy (table 4). The most common adverse events (grades 1 and 2) were diarrhea, headache, and nausea, with no significant differences between groups. Four patients reported severe adverse events (headache alone or with diarrhea); however, they were more frequent in the placebo arm. Discolored urine is a known side effect of nitazoxanide therapy, which might raise concerns about inadvertent unblinding. However, although this event was indeed more frequent in the treatment arm, it was also reported by patients receiving placebo (5.6% versus 1.5%, respectively) (table 3).

In this multicenter, double-blind, randomized, placebo-controlled trial of patients with mild Covid-19, we found that symptom resolution (dry cough, fever, and fatigue) did not differ between the nitazoxanide and placebo after 5 days of therapy. Nitazoxanide was safe, significantly reduced viral load, and increased the proportion of patients testing negative for SARS-CoV-2 after 5 days of therapy compared to placebo.

Nitazoxanide did not prevent hospitalization or effect any change in complete blood count, CRP levels, or serum biomarkers of inflammation. Moreover, nitazoxanide is inexpensive, widely available, and, to date, no other recommended therapies have been demonstrated to provide any benefit in this population.

There is an urgent need for evidence-based pharmacotherapeutics for Covid-19. In the challenging context of a pandemic, drug repurposing can reduce the time-consuming drug development process and allow rapid deployment of effective therapies to the population [2] . Before implementation of this trial, the NIH Clinical Collection (NCC) library, a collection of 727 FDA-approved drugs or drug-like compounds with a history of use in human clinical trials, was screened for potential in vitro antiviral activity against SARS-CoV-2 (supplementary figure S1). Nitazoxanide and tizoxanide, its active metabolite, significantly reduced viral load in VeroE6, human embryonic kidney (HEK 293T), and lung epithelial (Calu-3) cells infected with SARS-CoV-2, without inducing loss of cell viability. The adverse effect profile of nitazoxanide is well-known, since it has been commercially available and used in the clinic since 1996; indeed, a commercial formulation was used in this trial. A dosage regimen of 500 mg every 12 hours is approved and commonly prescribed for treatment of intestinal parasitosis [5] , with few reported adverse events. In our study, the same dose was administered, but every 8 hours, based on in vitro pharmacological studies by our group and published data on plasma concentration [6] [7] [8] , in order to maximize potential inhibition of SARS-CoV2 in vivo [7] . We assumed that high ratios of maximum serum concentration at doses safe in humans to maximal in vitro effective antiviral concentration would translate into higher potential to achieve viral suppression at approved doses [10] .

Nitazoxanide failed to meet the primary outcome in patients with mild Covid-19 when evaluated after 5 days of therapy. Consistent with the in vitro data, we observed significant reductions in viral load after a 5-day course of nitazoxanide in patients with mild Covid-19. This effect may have epidemiological impact, potentially decreasing community spread of SARS-CoV-2 [9, 10] , morbidity [11] , and mortality [12] .

We enrolled patients with mild Covid-19 as soon as possible after symptom onset because antivirals seem to be more effective at this stage of infection [13] . The cutoff point for enrollment was 3 days after onset of first symptom; however, as therapy was begun only after confirmation of SARS-CoV-2 infection, the median timing of treatment initiation was 5 (4-5) days after symptom onset (table 1 This study has several limitations. Only three symptoms (dry cough, fever, and fatigue) were considered for analysis of primary outcome, even though Covid-19 is now known to have protean manifestations and patients reported other symptoms. Patients were followed during the 5-day course of therapy; however, a long-term analysis of the effects of therapy should be performed. All patients were instructed to take their study medication 3 times daily as prescribed, return to the study site if symptoms worsened or adverse effects developed, and complete their symptom journals with data on any adverse events, the intensity of each Covid-19 symptom, and when symptoms abated and resolved. However, we cannot ascertain the extent to which patients followed these instructions. Nevertheless, given the placebo-controlled design, nonadherence may have occurred in both groups. In the nitazoxanide group, around 3% stopped therapy due to gastrointestinal upset after Covid-19 symptoms had already improved. Finally, no chest computed tomography scans or plain radiographs were obtained in these patients, since our work was mostly performed at freestanding mobile urgent care centers.

In summary, in patients with mild Covid-19 enrolled within 3 days of symptom onset, nitazoxanide as compared with placebo was not an effective therapy in terms of accelerating symptom resolution after 5 days of therapy, and did not modify clinically relevant secondary outcomes. However, nitazoxanide was safe, significantly decreased viral load, and increased the proportion of patients who tested negative for SARS-CoV-2 after completion of therapy.

Hung Data are n (%) and include all adverse events reported after nitazoxanide or placebo. 

Early use of nitazoxanide in mild Covid-19 disease: randomized, placebocontrolled trial FBS, 1% L-glutamine and 1% penicillin/streptomycin, and maintained as described above.

The 

We explored the repurposing potential of existing drugs for anti-SARS-CoV-2 activity and selected nitazoxanide, a broad-acting antiparasitic and antiviral compound [1, 2] , as a candidate for clinical testing amongst more than 700 compounds (Figure S1A-B) . Virology studies relevant to clinical translation were performed in preclinical infection systems using human embryonic kidney (HEK293T) (Figure S1D-F) and human pulmonary epithelial (Calu-3) cell lines (Figure S1G-I) . Both nitazoxanide and tizoxanide have specific antiviral activity against SARS-CoV-2 ( Figure S1C-I) with an appropriate therapeutic index (Figure S1J-L) . Notably, the concentrations of nitazoxanide and tizoxanide with in vitro anti-SARS-CoV-2 activity were within the concentrations attained with therapeutic dose ranges in healthy volunteers [3] , implying that they are likely to achieve target concentrations to suppress SARS-CoV-2 under safe dosing conditions [4] . Beyond its well-documented preclinical antiviral activity, additional advantages of nitazoxanide as a repurposing candidate include its favorable oral bioavailability and tolerability in doses well in excess of the usual therapeutic dose range [3] [4] [5] . Nitazoxanide is available worldwide, inexpensive to produce and procure, and safe, with a vast body of clinical data accumulated in clinical trials and postmarketing experience, including over 75 million doses with no serious adverse effects reported [6] .

To begin exploring the repurposing potential of existing drugs against SARS-CoV-2 infection, Compounds were ranked on the basis of reduction of SARS-CoV-2-induced CPE (mean values from both HTS runs). Five compounds reduced CPE by more than 60% and were considered hit candidates, including nitazoxanide (which was selected for follow-up in vitro studies) and its active metabolite, tizoxanide.

To Experiments performed with these compounds at 10 and 32 mM reduced viral RNA levels by at least 10-fold on average ( Figure S1D ). The reduction in viral RNA levels in cell cultures treated with nitazoxanide or tizoxanide was accompanied by a more significant reduction in infectious SARS-CoV-2 in supernatant samples, in which nitazoxanide or tizoxanide treatment reduced viral titers by approximately 100-fold at 10 µM or to undetectable levels at 32 µM ( Figure S1E ).

Representative SARS-CoV-2 plaque-forming assay images in Figure S1F illustrate the decrease in number of SARS-CoV-2 lysis plaques (white dots) in samples from experimental groups treated with nitazoxanide or tizoxanide in comparison to the DMSO (vehicle)-treated group.

Briefly, virus lysis plaques are observed in vehicle-treated groups up to a 10 -4 sample dilution factor, while nitazoxanide or tizoxanide treatment causes virus lysis plaques to disappear from samples diluted 10 -2 and forward.

Following the results in the HEK293T cell line, treatment of infected Calu-3 cell cultures with nitazoxanide or tizoxanide at 10 µM reduced RNA levels by 3-to 5-fold, while treatment with 32 µM resulted in an at least 18-fold reduction ( Figure S1G) . The antiviral effect of nitazoxanide and tizoxanide was more pronounced on the infective SARS-CoV-2 load, in which treatment with either compound at 10 µM resulted in a 10-to 20-fold reduction, while treatment at 32 µM reduced viral load by approximately 1000-fold ( Figure S1H ). Representative images of the plaque-forming assays used to determine the infective viral load in experiments using Calu -3 cells illustrate the decrease in the number of viral lysis plaques in groups exposed to nitazoxanide or tizoxanide ( Figure S1I) . Samples from untreated SARS-CoV-2 infected groups show virus lysis plaques up to the 10 -4 dilution factor, which indicates high viral titers. Samples from groups receiving nitazoxanide or tizoxanide at 32µM show fewer lysis plaques at the lower dilution factor (10 -1 ), indicating a reduced viral titer.

Non-infected Vero CCL81, HEK293T, and Calu-3 cell culture plates were prepared in parallel to the antiviral assay plates to assess potential in vitro toxicity (Figure S1J-L) . Cell cultures were incubated with nitazoxanide, tizoxanide, or DMSO for 24h or 48h (depending on the cell type)

and an MTT assay was performed to assess cell culture viability. The results showed that nitazoxanide and tizoxanide caused no significant reduction in Vero CCL81 (Figure S1J 

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of

Cases From the Chinese Center for Disease Control and Prevention

Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Efficacy and safety of nitazoxanide, albendazole, and nitazoxanidealbendazole against Trichuris trichiura infection: a randomized controlled trial

Nitazoxanide: pharmacokinetics and metabolism in man

Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses

Virological assessment of hospitalized patients with COVID-2019

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

SARS-CoV-2 viral load predicts COVID-19 mortality

SARS and MERS: recent insights into emerging coronaviruses

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Patients with one or more of three selected symptoms of Covid-19 (fever and/or dry cough

Exclusion criteria: 1. Negative result on RT-PCR for SARS-CoV-2 in a nasopharyngeal swab specimen collected at admission

Inability to swallow

Chronic kidney disease requiring renal replacement therapy

Severe heart failure (NYHA class 3 and class 4)

Severe chronic obstructive pulmonary disease (COPD) (GOLD 3 and 4)

Por favor

Qual a intensidade da sua TOSSE SECA? Sendo (1) sem tosse seca e (5) tosse de intensidade insuportável

) nenhuma dor e (5) dor de garganta de intensidade insuportável

) nenhuma dor e (5) dor de cabeça de intensidade insuportável

Qual a intensidade das suas DORES MUSCULARES? Sendo (1) nenhuma dor e (5) dor de intensidade insuportável

Qual a intensidade da seu DESCONFORTO RESPIRATORIO? Sendo (1) nenhum desconforto e (5) desconforto de intensidade insuportável

Você apresenta DIARREIA? Sendo (1) nenhum sintoma e (5) diarréia de alta intensidade

Sendo (1) nenhum sintoma e (5) diarréia de alta intensidade

Por favor

Qual a intensidade da sua TOSSE SECA? Sendo (1) sem tosse seca e (5) tosse de intensidade insuportável

) nenhuma dor e (5) dor de garganta de intensidade insuportável

) nenhuma dor e (5) dor de cabeça de intensidade insuportável

Qual a intensidade das suas DORES MUSCULARES? Sendo (1) nenhuma dor e (5) dor de intensidade insuportável

Qual a intensidade da seu DESCONFORTO RESPIRATORIO? Sendo (1) nenhum desconforto e (5) desconforto de intensidade insuportável

Você apresenta DIARREIA? Sendo (1) nenhum sintoma e (5) diarréia de alta intensidade

Por favor

Qual a intensidade da sua TOSSE SECA? Sendo (1) sem tosse seca e (5) tosse de intensidade insuportável

) nenhuma dor e (5) dor de garganta de intensidade insuportável

) nenhuma dor e (5) dor de cabeça de intensidade insuportável

Qual a intensidade das suas DORES MUSCULARES? Sendo (1) nenhuma dor e (5) dor de intensidade insuportável

Qual a intensidade da seu DESCONFORTO RESPIRATORIO? Sendo (1) nenhum desconforto e (5) desconforto de intensidade insuportável

Você apresenta DIARREIA? Sendo (1) nenhum sintoma e (5) diarréia de alta intensidade

Por favor

Qual a intensidade da sua TOSSE SECA? Sendo (1) sem tosse seca e (5) tosse de intensidade insuportável

) nenhuma dor e (5) dor de garganta de intensidade insuportável

) nenhuma dor e (5) dor de cabeça de intensidade insuportável

Qual a intensidade das suas DORES MUSCULARES? Sendo (1) nenhuma dor e (5) dor de intensidade insuportável

Qual a intensidade da seu DESCONFORTO RESPIRATORIO? Sendo (1) nenhum desconforto e (5) desconforto de intensidade insuportável

Você apresenta DIARREIA? Sendo (1) nenhum sintoma e (5) diarréia de alta intensidade

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

Nitazoxanide: a new thiazolide antiparasitic agent

Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses

Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis

Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy--A formal TQT study

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

The Use of Denaturing Solution as Collection and Transport Media to Improve SARS-CoV-2 RNA Detection and Reduce Infection of Laboratory Personnel

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful?

Remdesivir for the Treatment of Covid-19 -Final Report

The authors thank Moira Elizabeth Schöttler (Rio de Janeiro, Brazil) and Filippe Vasconcellos (São Paulo, Brazil) for editing assistance.

The trial statistician, not involved with patient enrollment or care, obtained a computer-generated randomization list (random.org). Participants were randomized (1:1 ratio) using this list to either the control arm (group B, placebo) or the intervention arm (group A, nitazoxanide). The study treatment (A or B) was revealed to the pharmacist only after patients were registered in the system, ensuring proper concealment of the allocation sequence. The designated pharmacist at each study site was the only person aware of group allocation throughout the trial.

A secure website was created by the information technology group (see Committees, Leadership, and Investigators) for data entry, validation, collection, and export. Site investigators, ACTGen monitors, and executive committee members were assigned a secure login and encrypted passwords (128-bit hash). The SARITA-2 system was built on ASP.NET MVC5 with an SQL Server database as the general system; ASP.NET MVC5 as the Web layer; DDD architecture with dependency injection and control inversion as the backend; jQuery with Bootstrap as the frontend; and SQL Server with Entity Framework (Migrations) for data entry and access. The system was hosted in Azure App Service, layer S1 (Microsoft Cloud).Upon registration of a patient in the system, a unique trial identifier and barcode number (for laboratory tests) were generated and the patient was randomly allocated into group A or B, as mentioned above. Forms within the system were divided into sections that allowed registration of: 1demographic data (contact information, patient demographic data, general comments) and upload of informed consent forms; 2study day 1 (Baseline): symptoms, vital signs, swab collection data, and results; 3 -Patients who test positive for SARS-CoV-2 (result obtained 1-2 days after RT-PCR, returned to the health facility: clinical data, PCR results, blood test results; 4 -After 5 days of therapy: clinical information, PCR results, blood test results; and 5 -One week after completion of therapy: clinical information, when necessary.

At day 1 (baseline), a nasopharyngeal swab was collected from patients for molecular confirmation of SARS-CoV-2 infection by RT-PCR. Up to 48 hours later, RT-PCR results were displayed. If negative, patients would be excluded from the study. If positive, patients were invited to return to the study site for clinical and laboratory evaluation and initiation of treatment (nitazoxanide 500 mg or placebo, every 8 hours for 5 days, as per group allocation). Patients were given a thermometer and instructed to complete a self-administered questionnaire, which consisted of a list of symptoms and scales on which to record their intensity on each day of therapy (Table S2 ). Patients were also instructed to return to the study site if any adverse event occurred. One day before completion of therapy, patients received a phone call to remind them to come back to the study site on the next day for final evaluation. Every included patient was followed according to the following data collection plan:1. Clinical evaluation (fever, dry cough, fatigue): daily during the course of therapy (via selfadministered questionnaire).2. Nasopharyngeal swab collection for viral load assessment by RT-PCR: at baseline and 1 day after completion of the 5-day course of therapy.3. Complete blood cell count and C-reactive protein (CRP): immediately before the first dose of study drug and 1 day after completion of the 5-day course of therapy.4. Serum levels of selected proinflammatory mediators: immediately before the first dose of study drug and 1 day after completion of the 5-day course of therapy.

Nasopharyngeal swab samples obtained from each patient were collected in a single tube containing 2 mL of guanidine isothiocyanate transport solution, as previously described [7] .Extraction of the total RNA from collected specimens was performed using the QIAamp Viral There, they were stored at -80 °C for molecular analysis of inflammatory mediators.

Serum from patients was evaluated for the following biomarkers: interleukin (IL)-6, IL-8, IL-1β, tumor necrosis factor (TNF)-, and interferon (IFN)-γ.were measured with commercially available ELISA kits, following the manufacturer's recommendations (Peprotech Inc., Ribeirão Preto, São Paulo, Brazil).

This study evaluated efficacy and safety outcomes. 1. Incidence of adverse events (AEs) throughout the study.2. Rate of treatment discontinuation due to AEs.All outcomes were assessed by blinded investigators. We conducted source data verification of the D8 assessment from study sites and laboratory forms for all patients at sites.

Initially, we planned on following patients until D8, regardless of final RT-PCR test result.

Calculation of the sample size was based on a previous study which demonstrated that 78% of Covid-19 patients in group 4 (Hospitalized without oxygen therapy), according to the WHO ordinal classification, experienced complete resolution of symptoms after receiving placebo [10] .In the present trial, patients were classified as group 2 (Symptomatic and independent), and a greater degree of recovery as measured by symptom-free days (80%) was expected even after placebo. Thus, assuming an 11% increase in symptom-free days in those patients who would receive nitazoxanide compared to placebo, we would need approximately 196 patients per experimental group, admitting a beta error of 15% and alpha error of 5%, for a total n of 392 patients.